Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on September 24, 2020. The filing reports on corporate governance changes effective immediately on the date of the report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
The primary material change reported is the election of Dr. Rita Balice-Gordon, Ph.D., as a director of the Company and a member of the Nominating and Corporate Governance Committee. She serves as a Class I director with an initial term expiring at the 2021 annual meeting of shareholders.
Compensation and Governance Details
- Cash Retainers: Dr. Balice-Gordon will receive an annual cash retainer of $50,000 for Board service and $5,000 for service on the Nominating and Corporate Governance Committee, prorated based on the effective date.
- Equity Grants: The Board granted an option to purchase 10,055 shares of common stock at the closing price on the grant date, and 5,027 restricted stock units (RSUs).
- Vesting: Both the stock option and RSUs vest on the first anniversary of the grant date, subject to continued service.
- Indemnification: An indemnification agreement was entered into effective September 24, 2020.
The filing states there are no related party transactions involving Dr. Balice-Gordon reportable under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 10,055 new options and 5,027 RSUs on dilution.
- Confirm the closing stock price on September 24, 2020, to determine the exercise price of the granted options.
- Review the Company's non-employee director compensation policy to ensure the grants align with standard practices for the firm.
- Check subsequent filings for the formal press release referenced as Exhibit 99.1.